Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

workflow

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

The drug is now the first ALK inhibitor to show disease-free survival benefit in this patient population

Top 10 Most Important Advisor Questions: Key Brand Attributes

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's the first one to keep...

Impetus Digital

- PMLiVE

NHS England to offer world-first seven-minute cancer treatment injection

Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%

- PMLiVE

Roche’s spinal muscular atrophy therapy Evrysdi approved by EC for newborns

The neuromuscular disease affects approximately one in every 10,000 babies

Top 10 Most Important Advisor Questions: Unmet Needs

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's the first one to keep...

Impetus Digital

Amplifying Opinions of Patients & Caregivers for Higher Quality of Care

Pam Cusick, Senior Vice President of Rare Patient Voice, dives into diversity, equity, and inclusion in Pharma and clinical trials; ways to enhance the patient’s voice in their treatment journey...

Impetus Digital

- PMLiVE

Roche’s Genentech and Blueprint receive full FDA approval for Gavreto in lung cancer

The targeted therapy was granted accelerated approval for the NSCLC indication in 2020

Expanding Opportunities for Healthcare with “Digital Twins”

Brad Womble, Senior Director of Strategy, Marketing and Mergers & Acquisitions, at Jabil Healthcare dives into several thought-provoking topics, including how insights from “digital twins” can be used to improve...

Impetus Digital

- PMLiVE

Roche’s spinal muscular atrophy therapy recommended by CHMP for newborns

Evrysdi is already approved in the EU to treat SMA patients aged two months or older

- PMLiVE

Roche partners with Alnylam on hypertension therapy in deal worth up to $2.8bn

Zilebesiran is in phase 2 development to treat hypertension in patients with high-unmet needs

Engaging KOLs & Gaining Insights in Pharma’s New Normal

Kaitlin Anstett, Senior Medical Advisor at Theratechnologies, shares her unique insights into the way Medical Affairs teams are changing the way they are engaging and interacting with their most important...

Impetus Digital

Mobilizing Agitation Detection in Children with ADHD

Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links